CN102206487B - Carboxylation beta-cyclodextrin modified low-toxicity functional quantum dot and preparation method thereof - Google Patents
Carboxylation beta-cyclodextrin modified low-toxicity functional quantum dot and preparation method thereof Download PDFInfo
- Publication number
- CN102206487B CN102206487B CN 201110100075 CN201110100075A CN102206487B CN 102206487 B CN102206487 B CN 102206487B CN 201110100075 CN201110100075 CN 201110100075 CN 201110100075 A CN201110100075 A CN 201110100075A CN 102206487 B CN102206487 B CN 102206487B
- Authority
- CN
- China
- Prior art keywords
- beta
- cyclodextrin
- quantum dot
- folic acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 94
- 239000001116 FEMA 4028 Substances 0.000 title claims abstract description 85
- 229960004853 betadex Drugs 0.000 title claims abstract description 85
- 239000002096 quantum dot Substances 0.000 title claims abstract description 82
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title claims abstract description 49
- 235000011175 beta-cyclodextrine Nutrition 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 231100000053 low toxicity Toxicity 0.000 title abstract 6
- 230000021523 carboxylation Effects 0.000 title abstract 4
- 238000006473 carboxylation reaction Methods 0.000 title abstract 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 95
- 235000019152 folic acid Nutrition 0.000 claims abstract description 55
- 239000011724 folic acid Substances 0.000 claims abstract description 55
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960000304 folic acid Drugs 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 11
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000004048 modification Effects 0.000 claims abstract description 9
- 238000012986 modification Methods 0.000 claims abstract description 9
- 239000011701 zinc Substances 0.000 claims abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052709 silver Inorganic materials 0.000 claims abstract description 4
- 239000004332 silver Substances 0.000 claims abstract description 4
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000008367 deionised water Substances 0.000 claims description 18
- 229910021641 deionized water Inorganic materials 0.000 claims description 18
- 229940064302 folacin Drugs 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 15
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 14
- 230000004913 activation Effects 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 238000013019 agitation Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 11
- 238000010168 coupling process Methods 0.000 claims description 11
- 238000005859 coupling reaction Methods 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- -1 collect elutriant Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 230000021615 conjugation Effects 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 claims description 8
- 229950004394 ditiocarb Drugs 0.000 claims description 8
- 230000037452 priming Effects 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 238000010898 silica gel chromatography Methods 0.000 claims description 8
- 238000010792 warming Methods 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 claims description 4
- 101710134784 Agnoprotein Proteins 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 230000001143 conditioned effect Effects 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 4
- 238000013016 damping Methods 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 229960004756 ethanol Drugs 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 239000001117 sulphuric acid Substances 0.000 claims description 4
- 235000011149 sulphuric acid Nutrition 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- UWLMQFDPGCYPBE-UHFFFAOYSA-N 3-chloropropanoic acid;sodium Chemical compound [Na].OC(=O)CCCl UWLMQFDPGCYPBE-UHFFFAOYSA-N 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical group [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- CXGWHMJRIQWYRK-UHFFFAOYSA-N [Na].ClCCCC(=O)O Chemical compound [Na].ClCCCC(=O)O CXGWHMJRIQWYRK-UHFFFAOYSA-N 0.000 claims description 2
- WBQZSGRHNVSHML-UHFFFAOYSA-N [Na].OC(=O)CCBr Chemical compound [Na].OC(=O)CCBr WBQZSGRHNVSHML-UHFFFAOYSA-N 0.000 claims description 2
- XHWDALZMZIHQSV-UHFFFAOYSA-N [Na].OC(=O)CCCBr Chemical compound [Na].OC(=O)CCCBr XHWDALZMZIHQSV-UHFFFAOYSA-N 0.000 claims description 2
- 238000001311 chemical methods and process Methods 0.000 claims description 2
- 229910052738 indium Inorganic materials 0.000 claims description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 2
- 238000003828 vacuum filtration Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 238000000295 emission spectrum Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 abstract 1
- 238000007385 chemical modification Methods 0.000 abstract 1
- 238000001917 fluorescence detection Methods 0.000 abstract 1
- 150000002224 folic acids Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 238000006862 quantum yield reaction Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 10
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 9
- 239000007850 fluorescent dye Substances 0.000 description 7
- CUJVBAPGYBSBHJ-YWBSARSQSA-N 2-[[(1R,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21R,23R,25R,26R,28R,30R,31R,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,38,40,42-tetrakis(carboxymethoxy)-10,15-bis(carboxymethoxymethyl)-37,39,41,43,44,45,46,47,48,49-decahydroxy-20,25,30,35-tetrakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]acetic acid Chemical compound OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](OCC(O)=O)[C@H]2O)[C@H](O)[C@H]5OCC(O)=O)[C@H](O)[C@H]4OCC(O)=O)[C@H](O)[C@H]3OCC(O)=O CUJVBAPGYBSBHJ-YWBSARSQSA-N 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940014144 folate Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 229940043267 rhodamine b Drugs 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000695 excitation spectrum Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910004613 CdTe Inorganic materials 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 1
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004054 semiconductor nanocrystal Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000001149 thermolysis Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110100075 CN102206487B (en) | 2011-04-21 | 2011-04-21 | Carboxylation beta-cyclodextrin modified low-toxicity functional quantum dot and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110100075 CN102206487B (en) | 2011-04-21 | 2011-04-21 | Carboxylation beta-cyclodextrin modified low-toxicity functional quantum dot and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102206487A CN102206487A (en) | 2011-10-05 |
CN102206487B true CN102206487B (en) | 2013-08-21 |
Family
ID=44695557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110100075 Expired - Fee Related CN102206487B (en) | 2011-04-21 | 2011-04-21 | Carboxylation beta-cyclodextrin modified low-toxicity functional quantum dot and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102206487B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103182298B (en) * | 2013-03-28 | 2015-04-22 | 江苏大学 | Synthesis of L-tryptophan derived beta-cyclodextrin bonded silica gel and application thereof for separating alanine enantiomers |
CN104250552B (en) * | 2013-06-25 | 2016-06-22 | 华东理工大学 | The method of water-soluble CdS quantum dot-beta cyclodextrin clathrate prepared by supercritical carbon dioxide |
CN105803806A (en) * | 2016-04-21 | 2016-07-27 | 安徽皖翎羽绒制品有限公司 | Treatment method of down feather with long-acting electromagnetic radiation shielding effect |
CN107855540B (en) * | 2017-11-24 | 2019-08-02 | 河南科斗新材料研究院有限公司 | A kind of preparation method of Properties of Oil-Soluble Ag Nanoparticles |
CN109682871B (en) * | 2019-01-16 | 2021-04-16 | 扬州大学 | beta-CD @ CdS nanorod applied to photoelectric biosensing and preparation method thereof |
CN109825284B (en) * | 2019-01-23 | 2022-01-25 | 东莞理工学院 | Ethylenediamine-beta-cyclodextrin modified Mn doped ZnS quantum dot and preparation method and application thereof |
CN115075023B (en) * | 2022-07-12 | 2024-02-06 | 百草边大生物科技(青岛)有限公司 | Preparation method of large biological water-based synthetic leather containing tea active ingredients |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101806795A (en) * | 2010-03-29 | 2010-08-18 | 中山大学 | Tumor-targeting functionalized quantum dot and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006118543A1 (en) * | 2005-05-04 | 2006-11-09 | Agency For Science, Technology And Research | Novel water-soluble nanocrystals comprising a low molecular weight coating reagent, and methods of preparing the same |
-
2011
- 2011-04-21 CN CN 201110100075 patent/CN102206487B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101806795A (en) * | 2010-03-29 | 2010-08-18 | 中山大学 | Tumor-targeting functionalized quantum dot and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
Antonio Clementi,et al..Synthesis and characterization of a collidal novel folic acid-β-cyclodextrin conjugate for targeted drug delivery.《J.Incl.Phenom.Macrocycl.Chem.》.2010,第69卷第323页. |
Synthesis and characterization of a collidal novel folic acid-β-cyclodextrin conjugate for targeted drug delivery;Antonio Clementi,et al.;《J.Incl.Phenom.Macrocycl.Chem.》;20100130;第69卷;第321-325页 * |
Also Published As
Publication number | Publication date |
---|---|
CN102206487A (en) | 2011-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102220128B (en) | Low-toxicity functionalized quantum dot modified by amination beta-cyclodextrin and preparation method thereof | |
CN102206487B (en) | Carboxylation beta-cyclodextrin modified low-toxicity functional quantum dot and preparation method thereof | |
Yao et al. | Upconversion luminescence nanomaterials: A versatile platform for imaging, sensing, and therapy | |
Liu et al. | Design of NIR-II high performance organic small molecule fluorescent probes and summary of their biomedical applications | |
CN101440282B (en) | Near-infrared fluorescent molecular probe, synthesizing method and use thereof | |
Meng et al. | Recent advances in near‐infrared‐II fluorescence imaging for deep‐tissue molecular analysis and cancer diagnosis | |
Wu et al. | Nanobody modified high-performance AIE photosensitizer nanoparticles for precise photodynamic oral cancer therapy of patient-derived tumor xenograft | |
Gao et al. | Supramolecular adducts of squaraine and protein for noninvasive tumor imaging and photothermal therapy in vivo | |
JP6606487B2 (en) | Substituted silaxanthenium red to near-infrared fluorescent dyes for in vitro and in vivo imaging and detection | |
US9365721B2 (en) | Polycyclo dyes and use thereof | |
Yu et al. | Near-infrared fluorescence imaging using organic dye nanoparticles | |
CN109276721A (en) | It is a kind of to target mesoporous poly-dopamine multifunctional nano diagnosis and treatment agent and the preparation method and application thereof | |
Wei et al. | Rigid and photostable shortwave infrared dye absorbing/emitting beyond 1200 nm for high-contrast multiplexed imaging | |
CN109395079B (en) | Multifunctional nano probe and preparation method and application thereof | |
Ou et al. | Molecular design of NIR-II polymethine fluorophores for bioimaging and biosensing | |
CN109313135B (en) | Aggregation-inducing luminophores for cancer cell imaging | |
CN101806795A (en) | Tumor-targeting functionalized quantum dot and preparation method thereof | |
Yue et al. | Research progress in the use of cationic carbon dots for the integration of cancer diagnosis with gene treatment | |
CN106420611A (en) | PH-sensitive chitosan drug-carrying micelle with targeting and fluorescent characteristics and preparation method thereof | |
Liu et al. | Aggregation-induced emission shining in the biomedical field: From bench to bedside | |
Zhu et al. | A DNA tetrahedron-loaded natural photosensitizer with aggregation-induced emission characteristics for boosting fluorescence imaging-guided photodynamic therapy | |
Teng et al. | Synthesis of strong electron donating-accepting type organic fluorophore and its polypeptide nanoparticles for NIR-II phototheranostics | |
CN103784978B (en) | A kind of albumen-dye composition and application thereof | |
Onyancha et al. | A review of the capabilities of carbon dots for the treatment and diagnosis of cancer-related diseases | |
Asgher et al. | Multifunctional materials conjugated with near-infrared fluorescent organic molecules and their targeted cancer bioimaging potentialities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU MAIJIAN BIO-TECH. DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: WUXI RONGXING SCIENCE + TECHNOLOGY CO., LTD. Effective date: 20130717 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 214028 WUXI, JIANGSU PROVINCE TO: 214043 WUXI, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130717 Address after: 214043, No. 401, North building, No. 836 Xingyuan North Road, Jiangsu City, Wuxi Province, 835 Applicant after: Jiangsu Maijian Bio-tech Development Co.,Ltd. Address before: 214028 No. 5, No. 7, Changjiang Road, New District, Jiangsu, Wuxi, 200 Applicant before: Wuxi Rongxing Technology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 214174, No. four, building 1, C District, life science and Technology Industrial Park, No. 1699, Huishan Road, Huishan District, Jiangsu, Wuxi Patentee after: JIANGSU MAIJIAN BIOTECHNOLOGY DEVELOPMENT CO., LTD. Address before: 214043, No. 401, North building, No. 836 Xingyuan North Road, Jiangsu City, Wuxi Province, 835 Patentee before: Jiangsu Maijian Bio-tech Development Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130821 Termination date: 20200421 |